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Ablation of Bscl2/seipin in hepatocytes does not cause metabolic
dysfunction in congenital generalised lipodystrophy
George D. Mcilroy1,2,*, Sharon E. Mitchell3, Weiping Han4, Mirela Delibegović2,5 and Justin J. Rochford1,2
ABSTRACT
Mutations affecting the BSCL2 gene cause the most severe form of
congenital generalised lipodystrophy (CGL). Affected individuals
develop severe metabolic complications including diabetes and
hepatic steatosis. Bscl2-deficient mice almost entirely reproduce
the CGL phenotype. Adipose tissue-specific loss of Bscl2 is also
sufficient to cause early-onset generalised lipodystrophy in mice.
However, thesemice do not show severemetabolic dysfunction, even
when challenged with a high-fat diet. Germline Bscl2 loss in mice
and BSCL2 disruption in humans causes severe hepatic steatosis,
and the encoded protein, seipin, has acknowledged roles in lipid
accumulation. Given the critical role of the liver in glucose regulation,
we speculated that intact hepatic Bscl2 expression may protect
adipose tissue-specific Bscl2-deficient mice from metabolic disease.
To investigate this, we generated a novel mousemodel in whichBscl2
has been deleted in both adipose tissue and hepatocytes
simultaneously using an adeno-associated viral vector. Despite
achieving efficient disruption of Bscl2 in the liver, hepatic lipid
accumulation and metabolic homeostasis was unaffected in mice fed
a high-fat diet for 4 weeks. We also investigated the consequences of
BSCL2 ablation in the human hepatocyte HepG2 cell line using
CRISPR/Cas9 genome editing. No significant increases in lipid
accumulation were observed in BSCL2 knockout cell lines. Overall,
we reveal that Bscl2/BSCL2 does not appear to play a cell-
autonomous role in the regulation of lipid accumulation in the liver.
Loss of hepatic BSCL2 is therefore unlikely to contribute significantly
to the development of hepatic steatosis or metabolic dysfunction in
this form of CGL.
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INTRODUCTION
The principal function of adipose tissue is to safely store energy that
is derived from the diet in the form of triglyceride (Rosen and
Spiegelman, 2014). However, numerous distinct adipose tissue
depots are known to exist, which are highly diverse and perform
specialised functions dependent upon their location within the body
(Zwick et al., 2018). Adipose tissue is also now well recognised as
an endocrine organ, playing a vital role in the regulation of energy
homeostasis and therefore overall metabolic health. This is clearly
highlighted by conditions of adipose tissue dysfunction. In obesity,
excessive levels of adiposity can lead to a lack of further lipid
storage capacity. The overflow of lipids to non-adipose tissues can
then lead to the development of metabolic complications such as
type 2 diabetes, hepatic steatosis and cardiovascular disease. An
inappropriate lack of functional adipose tissue can be equally
detrimental to metabolic health, as is observed in genetic or acquired
conditions of lipodystrophy (Hussain et al., 2019).
Congenital generalised lipodystrophy (CGL) type 2 (CGL2) is
the most severe form of lipodystrophy observed in humans and
results from mutations in the gene BSCL2 (Magré et al., 2001).
BSCL2 encodes the protein seipin, which is localised to the
endoplasmic reticulum (Windpassinger et al., 2004; Lundin et al.,
2006). The loss of adipose tissue in CGL2 affects both metabolic
and mechanical depots (Altay et al., 2017). Due to the inability to
safely store lipids in adipocytes, patients with this form of
lipodystrophy develop severe metabolic complications including
type 2 diabetes, hepatic steatosis and hyperlipidaemia (Hussain
et al., 2019). Therapeutic efforts have been made to treat the
lipoatrophic and metabolic phenotypes that arise in this condition;
however, these have been largely ineffective. For example, the
PPARγ agonist rosiglitazone, which activates the master regulator
of adipogenesis, failed to significantly increase fat mass stores in a
single patient receiving this treatment for a year (Victoria et al.,
2010). Alternatively, leptin-replacement therapy can be effective in
reducing appetite, partially resolving hepatic steatosis and
improving glycaemic regulation (Chong et al., 2010; Beltrand
et al., 2007). However, leptin therapy is not widely available, does
not resolve all features of CGL and prolonged use can lead to the
development of leptin antibodies and progression to leptin
resistance (Beltrand et al., 2010). Therefore, alternative treatment
strategies are urgently required.
Studies have also been performed using in vitro and in vivo
systems to model CGL2, in order to determine the molecular
function and mechanisms associated with seipin deficiency.
Inhibition of Bscl2 in cell culture models of adipogenesis clearly
indicate that seipin induction is an essential requirement for the
formation of adipocytes (Payne et al., 2008; Chen et al., 2009). Four
independent groups have also generated global Bscl2 knockout
mouse models (Cui et al., 2011; Chen et al., 2012; Prieur et al.,
2013; Mcilroy et al., 2018b), all of which almost entirely
recapitulate the metabolic phenotype observed in patients with
this condition (Dollet et al., 2014). We recently investigated the
consequences of adipose tissue-specific ablation of Bscl2 and were
surprised to discover that, despite the early development of
generalised lipodystrophy, metabolic dysfunction failed toReceived 11 October 2019; Accepted 10 December 2019
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manifest in male mice (Mcilroy et al., 2018b). This was also
observed in female mice, which only began to show subtle signs of
metabolic complications when placed at thermoneutrality and
challenged with a high-fat diet (Mcilroy et al., 2018a). These
findings led us to hypothesise that loss of seipin in non-adipose
tissues may contribute to the development of the full metabolic
phenotype in seipin-deficient individuals. If true, non-adipose
tissues could therefore become novel targets for therapeutic
intervention.
Recent studies have raised the possibility that seipin may play an
important, cell-autonomous role within the liver (Lounis et al.,
2017; Li et al., 2019). This organ plays a crucial role in lipid and
glucose homeostasis, both of which are perturbed in patients and
mice lacking seipin. Therefore, the presence of hepatic Bscl2 in our
adipose tissue-specific model might provide protection from the
development of metabolic disease. To investigate this, here we have
additionally ablated Bscl2 specifically in the hepatocytes of male
and female adipose tissue-specific Bscl2 knockout mice, using
adeno-associated viral vectors. Furthermore, we have generated
BSCL2 knockout lines in the human hepatocyte HepG2 cell model
using CRISPR/Cas9 genome editing. Overall, we find that the
additional ablation of seipin from hepatocytes fails to cause
development of metabolic dysfunction in vivo and does not lead
to alterations in triglyceride accumulation in vitro. Our findings
therefore indicate that seipin is unlikely to play a cell-autonomous
role in the regulation of lipid accumulation in the liver, even in the
background of lipodystrophy.
RESULTS
Characterisation of male adipose tissue-specific Bscl2-
deficient mice at thermoneutrality
Adipose tissue-specific Bscl2 knockout mice [Ad-B2(−/−)]
surprisingly failed to develop the severe metabolic dysfunction
observed in Bscl2 null mice, despite a similar generalised lack of
adipose tissue (Mcilroy et al., 2018b). Female Ad-B2(−/−) mice also
failed to develop metabolic dysfunction, even when housed at
thermoneutrality (30°C). Indeed, only moderate alterations to
metabolic homeostasis became apparent when female mice
housed at thermoneutrality were challenged with a high-fat diet
(Mcilroy et al., 2018a). We also previously showed that male Ad-
B2(−/−) mice have preserved brown adipose tissue (BAT) and
display increased markers of thermogenesis in residual epidydimal
white adipose tissue (EWAT) (Mcilroy et al., 2018b). To investigate
whether thermogenesis was offering any protection from metabolic
disease, we examined whether housing male Ad-B2(−/−) mice at
thermoneutrality would uncover the metabolic phenotype observed
in global Bscl2 knockout mouse models, which typically have used
male mice (Cui et al., 2011; Chen et al., 2012; Prieur et al., 2013;
Mcilroy et al., 2018b).
We placed a cohort of 11-week-old Ad-B2(+/−) and Ad-B2(−/−)
male mice fed a chow diet at thermoneutrality (30°C) for a
prolonged period of 21 weeks. We first confirmed the specificity of
Bscl2 ablation by quantitative PCR. Bscl2 mRNA transcript levels
were significantly decreased in EWAT in Ad-B2(−/−) male mice
compared to Ad-B2(+/−) control mice; however, no significant
differences in Bscl2 gene expression levels were detected in the liver
(Fig. 1A). No significant differences in body weight were observed
between the two genotypes, both prior to and throughout the
housing period at thermoneutrality (Fig. 1B). After 8 and 21 weeks
at thermoneutrality, dual-energy X-ray absorptiometry (DEXA)
analysis was performed. This revealed that Ad-B2(−/−) male mice
had significantly decreased fat mass (Fig. 1C) and significantly
increased lean mass (Fig. 1D), as a percentage of body weight,
compared to Ad-B2(+/−) controls. Absolute fat mass was also
significantly decreased at 8 and 21 weeks at thermoneutrality, and
absolute lean mass showed a trend towards being increased;
however, this was not significantly different at either time point
(Fig. S1A,B). Interestingly, although bone mineral density was not
significantly altered (Fig. S1C), both bone mineral content and bone
area were found to be significantly increased in Ad-B2(−/−) mice at
both time points (Fig. S1D,E). Dissected tissue weight of EWAT
was also significantly decreased, confirming the effect of Bscl2
ablation on adipose tissue development (Fig. 1E). Housing
Ad-B2(−/−) mice at thermoneutrality also led to a severe and
significant decrease in BAT tissueweight (Fig. 1E), compared to the
relatively well-preserved BAT depot we observed in Ad-B2(−/−)
mice maintained at standard housing temperatures (Mcilroy et al.,
2018b). Gene expression analysis of EWAT revealed significant
decreases in Adipoq and Lep in Ad-B2(−/−) mice compared to
Ad-B2(+/−) mice (Fig. 1F). Circulating serum levels of adiponectin
and leptin in mice fasted for 5 h also showed significant decreases
consistent with the changes in mRNA expression (Fig. 1G,H).
Both global Bscl2 knockout mice and male Ad-B2(−/−) mice have
been shown to display elevated gene expression levels of
thermogenic markers in residual EWAT depots (Chen et al., 2012;
Mcilroy et al., 2018b). To determine whether this was also the case
in male Ad-B2(−/−) mice housed at thermoneutrality, markers of
white and brown adipose tissue were examined. Levels of Pparg,
C/ebpa and Plin1 were significantly decreased in Ad-B2(−/−) mice
compared to controls; however, no significant changes were found
for aP2 (also known as Fabp4) (Fig. 1I). Curiously, significantly
increased expression of markers of thermogenesis such a Cpt1b and
Pgc1a (also known as Ppargc1a) were still apparent in residual
EWAT in male Ad-B2(−/−) mice. Additionally, expression of Ucp1
was observed in Ad-B2(−/−) mice; however, it was undetectable in
heterozygous control animals. No significant changes were observed
for Prdm16 between genotypes (Fig. 1I).
Male Ad-B2(−/−) mice housed at thermoneutrality do not
develop metabolic dysfunction
Female Ad-B2(−/−) mice housed at thermoneutrality and fed a chow
diet failed to develop the metabolic disease observed in global Bscl2
knockout mice (Mcilroy et al., 2018a). To determine whether this
was also the case in Ad-B2(−/−) male mice, we performed glucose
tolerance tests after housing mice at thermoneutrality for 9 weeks.
No significant differences were observed between genotypes when
the injected glucose bolus was normalised to body weight (Fig. 2A).
After housing mice at thermoneutrality for 21 weeks, glucose
tolerance tests were repeated. Due to the observed differences in the
percentage of lean mass between Ad-B2(+/−) and Ad-B2(−/−) mice
(Fig. 1D), we injected glucose normalised to lean mass levels to
determinewhether this was altering glucose clearance in Ad-B2(−/−)
male mice. Even under these conditions we observed no significant
alterations in glucose clearance between control and Ad-B2(−/−)
mice (Fig. 2B).
We next examined serum parameters to determine whether any
alterations were apparent. These were measured in mice that had
been housed at thermoneutrality for 21 weeks and had been fasted
for 5 h. A significant increase in circulating insulin was observed in
Ad-B2(−/−) mice (Fig. 2C); however, serum glucose levels and
quantitative insulin sensitivity check index (QUICKI) analysis
results were not significantly different (Fig. 2D,E), indicating that
male Ad-B2(−/−) mice were not insulin resistant. Serum triglyceride
levels were found to be significantly decreased in Ad-B2(−/−) male
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mice (Fig. 2F), which is also observed in global Bscl2 knockout
mice when fasted for similar periods (Cui et al., 2011; Chen et al.,
2012; Prieur et al., 2013). Liver triglyceride levels appeared to be
slightly elevated in Ad-B2(−/−) male mice compared to controls
(Fig. 2G); however, this difference was not significant. Liver gene
expression levels of Pparg, Srebp1c (also known as Srebf1) and
Scd1 were not significantly altered; however, a small but significant
decrease in Ppara expression was detected in Ad-B2(−/−) male
mice (Fig. 2H).
Overall, these results revealed that despite housing lipodystrophic
male Ad-B2(−/−) mice at thermoneutrality for a prolonged period of
time, this model fails to develop the severe metabolic dysfunction
observed in global Bscl2 knockout mouse models.
Additional ablation of hepatic Bscl2 in male and female
Ad-B2(−/−) mice
From the findings presented above along with previously published
data (Mcilroy et al., 2018a,b), it appears that adipose tissue-specific
deficiency of Bscl2 is insufficient to reproduce the metabolic
phenotype observed in global Bscl2 knockout mice. Indeed, all
other single tissue-specific Bscl2 deficient mouse models generated
to date have failed to report a metabolic phenotype (Chen et al.,
2014; Zhou et al., 2014; Xu et al., 2019). As BSCL2 is widely
expressed in several tissues (Magré et al., 2001), we hypothesised
that loss of Bscl2 in non-adipose tissues may be necessary for severe
metabolic dysfunction to develop in conditions of CGL2. We
therefore decided to additionally ablate Bscl2 in the liver of male
and female Ad-B2(−/−) mice using adeno-associated viral vectors,
due to the critical role of this tissue in regulating glucose and lipid
homeostasis.
To do this, we generated a cohort of 8- to 12-week-old male and
female Ad-B2(−/−) mice and examined basal (Pre-AAV) glucose
tolerance (Fig. 3A,B), body weight (Fig. 3C,D), fat mass (Fig. 3E,F)
and lean mass (Fig. 3G,H) levels. Mice were then randomised into
two groups that were not significantly different for each parameter.
Mice received intraperitoneal injections of 1.5×1011 genome copies
of an adeno-associated virus–thyroxine-binding globulin promoter–
eGFP (AAV-TBG-eGFP) control virus or adeno-associated
virus–thyroxine-binding globulin promoter–Cre recombinase vector
(AAV-TBG-iCre), in order to direct hepatocyte-specific
recombination and deletion of Bscl2. Mice were then fed a high-fat
diet (60% kcal from fat) and monitored for a period of 4 weeks at
standard housing temperatures (21°C). No significant alterations to
bodyweight (Fig. 3C,D), fat mass (Fig. 3E,F) or leanmass (Fig. 3G,H)
were observed in either male or female Ad-B2(−/−) mice injected
with AAV-TBG-iCre compared to AAV-TBG-eGFP control animals
during the 4-week monitoring period.
To confirm efficient and specific targeting of Bscl2 by the AAV-
TBG-iCre vector, we performed quantitative PCR analysis. Liver
Bscl2 gene expression levels were significantly decreased by ∼90%
in male mice (Fig. 3I) and by ∼80% in female mice (Fig. 3J).
However, no significant changes to Bscl2 gene expression were
detected in either the kidney or heart of male or female mice treated
with AAV-TBG-iCre compared to AAV-TBG-eGFP controls
(Fig. 3I,J). The data presented indicate that AAV-TBG-iCre
targeting of Bscl2 in Ad-B2(−/−) male and female mice is highly
Fig. 1. Male Ad-B2(−/−) mice housed at thermoneutrality are lipodystrophic. (A) Bscl2 mRNA levels in EWAT and liver of 32-week-old Ad-B2(+/−)
and Ad-B2(−/−) mice housed at thermoneutrality (30°C) for 21 weeks. (B) Body weight progression of Ad-B2(+/−) and Ad-B2(−/−) mice as described in A. (C,D) Fat
mass (C) and leanmass (D) levels assessed by DEXA and normalised to body weight in Ad-B2(+/−) and Ad-B2(−/−) mice after being housed at thermoneutrality for 8
and 21 weeks, respectively. (E) Tissue weights of EWAT and BAT of mice described in A normalised to body weight. (F) Relative gene expression levels of
adiponectin and leptin from EWATof mice described in A. (G,H) Serum adiponectin (G) and leptin (H) in mice described in A fasted for 5 h. (I) mRNA levels of white
and brown adipocytemarkers in EWATofmice described in A. All data are biological replicates presented as themean±s.e.m., n=6mice for each group, *P<0.05 vs
Ad-B2(+/−). nd, not detected.
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efficient and specific; therefore, establishing a novel mouse model
in which Bscl2 has been ablated in adipose tissue and hepatocytes
simultaneously. Importantly, this method of targeting does not lead
to alterations to body weight, fat mass or lean mass compared to
AAV-TBG-eGFP control animals.
Loss of hepatic Bscl2 in male and female Ad-B2(−/−) mice
does not cause metabolic dysfunction
We next determined whether the additional loss of hepatic Bscl2
would be sufficient to causemetabolic dysfunction in lipodystrophic
Ad-B2(−/−) mice. Glucose tolerance tests were performed 4 weeks
after mice had been injected with AAV-TBG-iCre vectors and fed a
high-fat diet. We found no significant differences in male or female
AAV-TBG-iCre mice compared to controls in their ability to clear
the injected glucose bolus (Fig. 4A,B). Similarly, when serum
insulin levels (Fig. 4C,D) or serum triglyceride levels (Fig. S1F,G)
were examined, no significant differences were observed.
Additionally, QUICKI analysis revealed that the additional loss of
hepatic Bscl2 had failed to induce insulin resistance in male or
female AAV-TBG-iCre mice compared to their AAV-TBG-eGFP
injected littermate controls (Fig. 4E,F).
We next investigated whether the ablation of Bscl2 in hepatocytes
in the background of lipodystrophy would lead to the development of
hepatic steatosis that is commonly observed in the global Bscl2
knockout mouse models. No significant alterations to liver
triglyceride levels were detectable in either male or female mice
(Fig. 4G,H), despite the substantial decrease in Bscl2 expression
levels within this tissue (Fig. 3I,J). Additionally, we observed no
significant alterations in hepatic gene expression levels of Pparg,
Srebp1c or Scd1 inmale or female AAV-TBG-iCremice (Fig. S1H,I).
We also saw no significant changes in Ppara expression in female
mice (Fig. S1I); however, once again, a small but significant decrease
in Ppara expression was detected in Ad-B2(−/−) male mice
(Fig. S1H). To determine whether there was any indication of the
development of liver damage in Ad-B2(−/−) mice injected with AAV-
TBG-iCre, we examined serum levels of alanine aminotransferase
(ALT) and alanine transaminase (AST). In agreement with a lack of
lipid accumulation in the liver and alterations to hepatic gene
expression levels, we found no significant alterations to ALT or AST
levels in male or female AAV-TBG-iCre mice compared to controls
(Fig. 4I,J). Similarly, no significant differences in the AST/ALT ratio
were detected (data not shown). Overall, our data indicate that loss of
Bscl2 in hepatocytes in the background of lipodystrophy fails to cause
metabolic dysfunction and the severe hepatic steatosis observed in
global Bscl2 knockout mice. Therefore, it would appear that Bscl2
loss in hepatocytes does not play a significant role in the development
of hepatic steatosis or glucose intolerance in seipin-deficient states,
even on a background of generalised lipodystrophy.
Ablation of BSCL2 in a human hepatocyte cell line does not
alter lipid accumulation
Our in vivo findings are in keeping with previously published data in
which liver-specific Bscl2 knockout mice did not develop glucose
intolerance or hepatic steatosis, even when challenged with a high-
fat diet (Chen et al., 2014). However, recent studies have indicated
that knockdown of Bscl2/BSCL2 in both primary mouse
hepatocytes and the human hepatocyte HepG2 cell line leads
to alterations in lipid droplet morphology and triglyceride
accumulation (Lounis et al., 2017). Additionally, a recent study
has also shown that overexpression of Bscl2 in mice may lead to
Fig. 2. Male Ad-B2(−/−) mice housed at thermoneutrality are not glucose intolerant. (A) Glucose tolerance tests (GTT) performed in Ad-B2(+/−) and
Ad-B2(−/−) mice housed at thermoneutrality for 9 weeks. The glucose bolus was normalised to body weight. (B) Glucose tolerance tests performed in
Ad-B2(+/−) and Ad-B2(−/−) mice housed at thermoneutrality for 21 weeks. The glucose bolus was normalised to lean mass. (C-F) Serum insulin (C), serum
glucose (D), QUICKI (E) and serum triglyceride (TG) levels (F) in Ad-B2(+/−) and Ad-B2(−/−) male mice housed at thermoneutrality for 21 weeks and fasted
for 5 h. (G) Liver TG levels normalised to tissue weight. (H) Relative gene expression levels of lipid-related markers in the liver of Ad-B2(+/−) and Ad-B2(−/−)
male mice. All data are biological replicates presented as the mean±s.e.m., n=6 (Ad-B2(+/−)) and n=5 (Ad-B2(−/−)) mice for each group, *P<0.05 vs Ad-B2(+/−).
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reductions in hepatic triglyceride levels (Li et al., 2019). These
findings therefore imply that Bscl2 could indeed play a cell-
autonomous role within the liver.
In order to investigate this further, we used CRISPR/Cas9
genome editing to knock out the BSCL2 gene in the human HepG2
hepatocyte cell line. To do this, we designed two guide RNA
(gRNA) sequences to target exon 2 and create a 97-bp deletion in
the BSCL2 gene (Fig. 5A). HepG2 cells were electroporated with
either the two gRNA sequences or a control plasmid (Ctrl), which
was used to generate a pool of unedited HepG2 cells, which had
otherwise been treated identically. We first analysed the Ctrl and
gRNA-electroporated populations by PCR to determine whether the
97-bp deletion was present. A minor PCR product was detectable at
the anticipated size (Fig. 5B). We next generated single-cell HepG2
populations from both the Ctrl and gRNA mixed populations by
serial dilution. PCR analysis indicated that a mixture of wild-type
(clones #23 and #24), heterozygous (clones #13 and #16) and
knockout (clones #17, #20 and #21) cell lines had been isolated,
whilst all Ctrl cell lines (clones #6, #7, #8 and #9) were wild type
(Fig. 5C). Clones #7 and #9 from Ctrl transfections and clones #17,
#20 and #21 from gRNA transfections were expanded, and PCR
analysis was repeated to confirm the previous results (Fig. 5D) and
obtain DNA sequencing analysis to assess successful genome editing
by CRISPR/Cas9 (Fig. 5E). We next established that the 97-bp
deletion had inactivated the BSCL2 protein product seipin by western
blot analysis. We observed that seipin was completely absent in all
three gRNA-transfected single-cell clones in comparison to Ctrl-
transfected clones, in which seipin was detectable at the appropriate
molecular mass (Fig. 5F).
Having generated three individual cell clones deficient in BSCL2,
we investigated whether loss of seipin in hepatocytes would lead to
any alterations in lipid accumulation. We plated each isolated clone
at similar cell densities and then determined lipid accumulation
levels by Oil Red O staining. We observed no obvious visual
differences in the amount of lipid accumulation between cell clones.
When we extracted and quantified the Oil Red O stain from HepG2
clones, we did observe a significant difference between Ctrl #7
compared to Ctrl #9 and gRNA #21 (Fig. 5G). These small
differences may result from natural variation in lipid storage when
single-cell populations are isolated. However, our data clearly
demonstrate that the complete ablation of BSCL2 does not
significantly increase lipid accumulation in hepatocytes. Overall,
our in vitro findings agree with our observations and those of others
in vivo, that loss of hepatic Bscl2 does not appear to cause severe
hepatic steatosis or metabolic dysfunction and is therefore unlikely
to play a significant cell-autonomous role in the regulation of lipid
accumulation within hepatocytes.
DISCUSSION
Individuals with homozygous mutations affecting the BSCL2 gene
develop the most severe form of CGL (Magré et al., 2001). This
disorder is characterised by the near complete absence of both
metabolic and mechanical adipose tissue depots and the
development of severe metabolic dysfunction (Altay et al., 2017;
Fig. 3. Characterising male and female Ad-B2(−/−) mice with AAV-mediated hepatic Bscl2 ablation. (A,B) Baseline (Pre-AAV) glucose tolerance tests
with glucose bolus normalised to body weight in male (A) and female (B) Ad-B2(−/−) mice. (C,D) Body weight progression of male (C) and female (D) Ad-B2(−/−)
mice injected with AAV-TBG-eGFP and AAV-TBG-iCre vectors and fed a high-fat diet for 4 weeks. (E-H) Fat mass (E,F) and lean mass (G,H) levels in male
and female mice at baseline (Pre-AAV), 2 or 4 weeks after AAV-TBG-eGFP or AAV-TBG-iCre injection assessed by EchoMRI and normalised to body weight.
(I,J) Relative Bscl2 mRNA levels in liver, kidney and heart of male (I) and female (J) AAV-TBG-eGFP and AAV-TBG-iCre mice. All data are biological replicates
presented as the mean±s.e.m., n=6 (eGFP) and n=5 (iCre) mice for males, n=7 (eGFP) and n=8 (iCre) mice for females, *P<0.05 vs AAV-TBG-eGFP.
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Hussain et al., 2019). Mouse models deficient in Bscl2 almost
entirely reproduce this phenotype (Cui et al., 2011; Chen et al.,
2012; Prieur et al., 2013; Mcilroy et al., 2018b), providing a
valuable in vivo tool to investigate and characterise this rare genetic
disorder. To explore this condition further, mouse models
examining the consequences of Bscl2 deficiency using tissue-
specific promoters have also been generated. Owing to the critical
role of adipose tissue in energy homeostasis, it is perhaps not
surprising that metabolic dysfunction was not reported when Bscl2
was depleted specifically in the liver (Chen et al., 2014), brain
(Zhou et al., 2014) or muscle (Xu et al., 2019). Unexpectedly,
however, glucose intolerance and severe hepatic steatosis was not
observed when we specifically targeted Bscl2 in adipose tissue
driven by Adipoq-Cre (Mcilroy et al., 2018b). Indeed, we have
failed to observe these metabolic consequences, which are found in
global Bscl2 knockout mice, even after challenging female Ad-
B2(−/−) mice with thermoneutral housing conditions and feeding
them a high-fat diet (Mcilroy et al., 2018a). We now also report that
male Ad-B2(−/−) mice housed at thermoneutrality also fail to
develop metabolic dysfunction. This reveals that preserved brown
adipose tissue thermogenesis and induction of thermogenic markers
in residual epidydimal white adipose tissue is unlikely to explain the
lack of glucose intolerance in these mice, despite generalised
lipodystrophy.
These findings led us to hypothesise that the development of
metabolic dysfunction in CGL2 may require the additional loss of
Bscl2 in non-adipose tissues. The liver appeared to be the most
likely tissue to buffer the effects of adipose loss for several reasons.
First, this organ plays a crucial role in glucose and lipid homeostasis.
Second, the development of severe hepatic steatosis is a hallmark
observed in patients and mice that are deficient in seipin (Dollet
et al., 2014; Akinci et al., 2016; Hussain et al., 2019). Third,
recent studies examining Bscl2/BSCL2 loss of function or its
overexpression in hepatocytes have indicated that seipin may play
an important cell-autonomous role in the liver (Lounis et al., 2017;
Li et al., 2019). To investigate this, we have used adeno-associated
viral vectors to generate a novel mouse model, in which Bscl2 has
been specifically ablated in both adipose tissue and hepatocytes
simultaneously. Despite significant decreases in liver Bscl2
expression levels in male and female Ad-B2(−/−) mice (∼90% and
∼80%, respectively), we observed no significant alterations to
multiple in vivo metabolic parameters compared to control mice,
even when challenged with a high-fat diet for 4 weeks. Our findings
are in keeping with those of Chen et al. (2014), where Bscl2 liver-
specific knockout mice failed to develop a metabolic phenotype
when fed either a chow or high-fat diet. Although we speculated that
the lack of lipodystrophy in that model may have protected against
metabolic dysfunction, our data now provide strong additional
evidence that Bscl2 is unlikely to play a cell-autonomous role in the
liver, even in the presence of lipodystrophy. We are unaware of any
other studies that have combined a genetically driven tissue-specific
knockout mouse model with AAV-Cre infection to selectively
ablate a gene of interest in an additional tissue. Indeed, we believe
that there may only be one other published study in which
genetically driven Cre recombination has been used to specifically
target a single gene in two tissue types (adipocytes and endothelial
cells) at the same time (Crewe et al., 2018). The novelty and ease of
our targeting method will therefore be broadly applicable to studies
Fig. 4. Male and female AAV-TBG-iCre mice do not develop metabolic dysfunction. (A,B) Glucose tolerance tests (Week 4) in which the glucose bolus
was normalised to body weight in male (A) and female (B) AAV-TBG-eGFP and AAV-TBG-iCre mice. (C-J) Serum insulin (C,D), QUICKI analysis (E,F), liver
TG levels (G,H) and serum AST and ALT levels in male (I) and female (J) AAV-TBG-eGFP and AAV-TBG-iCre mice fasted for 5 h. All data are biological
replicates presented as the mean±s.e.m., n=6 (eGFP) and n=5 (iCre) mice for males, n=7 (eGFP) and n=8 (iCre) mice for females.
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aiming to investigate the crosstalk between tissues and the
individual contributions of each.
In vitro investigations identifying a possible cell-autonomous
role for Bscl2/BSCL2 in hepatocytes achieved approximately a 50%
reduction in seipin protein levels by small interfering RNA (Lounis
et al., 2017). To investigate the complete absence of BSCL2 in
hepatocytes, we generated HepG2 BSCL2 knockout cell lines using
CRISPR/Cas9 genome editing. Despite the complete absence of
seipin protein, we found no significant increase in the amount of
triglyceride present in knockout cells. Although we have not
specifically investigated whether alterations to lipid droplet size or
morphology are present, our in vitro findings are consistent with our
in vivo studies. Together, these reveal that hepatic deficiency of
seipin does not appear to be responsible for significant increases in
hepatocyte lipid content or the severe hepatic steatosis that is
observed in global Bscl2 knockout mouse models or patients
suffering from CGL2.
If the additional loss of seipin in hepatocytes also fails to induce a
metabolic phenotype, then this raises important questions about the
differences between the global and conditional Bscl2 knockout
models. Our Bscl2 adipose tissue-specific knockout mice appear to
be similarly lipodystrophic compared to seipin knockout mice.
However, the infrapatellar fat pad was found to be well preserved in
Ad-B2(−/−) mice, yet completely absent in SKOmice (Mcilroy et al.,
2018b). Caudal marrow adipose tissue located in the vertebrae of the
tail was also present in Ad-B2(−/−) mice and is likely to be absent in
SKO mice, although this has yet to be examined. Therefore, our
previous findings (Mcilroy et al., 2018a,b), along with those
presented in this paper, would imply that these and other small
additional residual adipose tissue depots that remain may be
sufficient to prevent the development of metabolic dysfunction
associated with lipodystrophy in CGL2. Consistent with this notion,
adipose tissue transplantation studies have also been shown to
successfully alleviate the metabolic dysfunction observed in SKO
mice (Liu et al., 2018; Wang et al., 2019). Thus, our findings may
indicate that rescuing only very small quantities of endogenous
adipose tissue could be therapeutically beneficial as a treatment for
affected individuals. Nonetheless, if this is the case, it seems
remarkable that these small, preserved depots offer sufficient
protection from metabolic disease in Ad-B2(−/−) mice in the face
of high-fat feeding and thermoneutrality, when control mice
substantially expand their adipose depots.
Intriguingly, a recent study has shown that rescuing adipose
tissue in CGL2 could be a realistic possibility. Genetic loss of the
rate limiting enzyme of lipolysis, adipose triglyceride lipase (Atgl;
also known as Pnpla2), appeared to effectively rescue adipose tissue
development and prevent metabolic complications in SKO mice
(Zhou et al., 2019). The authors propose that Atgl is a direct
downstream target of Bscl2, where even heterozygous deletion of
Atgl seems to partially restore sufficient levels of adiposity to relieve
metabolic complications. This appears to occur by preventing the
increased rates of lipolysis from adipose tissue caused by
uncontrolled cAMP/PKA activation, as previously identified due
to Bscl2 deficiency (Chen et al., 2012). Aside from the inherent
challenges in achieving this, genetic manipulation of ATGL in
CGL2 would risk ectopic lipid accumulation in the heart, which led
Fig. 5. Ablation of BSCL2 in HepG2 cells does not alter lipid accumulation. (A) Schematic representation of CRISPR/Cas9 gRNA editing sites in exon
2 of BSCL2. (B) PCR identification of BSCL2 exon 2 deletion by CRISPR/Cas9 in a mixed population of HepG2 cells. KO, knockout; NTC, no template
control; WT, wild type. (C) PCR identification of single-cell HepG2 colonies containing BSCL2 exon 2 deletion isolated by serial dilution. (D,E) PCR analysis
of clones selected for expansion (D) and DNA sequencing (E) of PCR products confirming BSCL2 exon 2 deletion in HepG2 cells. (F) Western blot analysis
confirming the ablation of BSCL2 protein in HepG2 single cell clones with BSCL2 exon 2 deletion. (G) Representative images of Oil Red O-stained HepG2
cell clones (scale bars: 50 µm) and quantification of the eluted stain from biological replicates (n=8); data presented are from two independent experiments.
Data are presented as the mean±s.e.m., *P<0.05 vs Ctrl #7.
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to cardiac dysfunction and premature death of Atgl null mice in vivo
(Haemmerle et al., 2006). This would seem particularly the case in
CGL2 patients who typically display cardiomyopathy (Lupsa et al.,
2010). However, pharmacological inhibition of Atgl, using the
inhibitor Atglistatin, does not appear to cause the severe cardiac
steatosis or cardiomyopathy observed in genetic models of ATGL
disruption (Schweiger et al., 2017). It would be interesting to
determine whether Atglistatin can restore adipose tissue mass in
mature SKO mice. This seems unlikely if the lack of seipin leads to
stalling and then failure of adipogenesis as has been proposed,
which would result in a lack of nascent adipocytes on which the
Atglistatin could act (Payne et al., 2008; Chen et al., 2009, 2012).
Regardless of this, Zhou et al. (2019) have shown that adipose tissue
restoration is possible in CGL. Pagac et al. (2016) also suggested
that rescue of seipin-deficient pre-adipocytes may be possible
through pharmacological inhibition of glycerol-3-phosphate
acyltransferase 3 (Gpat3). However, the effects observed in vitro
were modest and the ability of Gpat3 inhibition to rescue adipose
tissue mass due to Bscl2 deficiency has not yet been examined
in vivo. Future studies investigating alternative pharmacological and
gene therapeutic approaches are therefore warranted. If successful,
these could prevent severe metabolic dysfunction in numerous
forms of lipodystrophy and metabolic complications that arise in




Bscl2 floxed mice (B2(fl/fl)) were generated as previously described
(Mcilroy et al., 2018b). To generate adipocyte-specific seipin knockout
mice (Ad-B2(−/−)), B2(fl/fl) mice were crossed with heterozygous Bscl2
floxed mice also carrying Cre recombinase driven by the Adipoq promoter
(Ad-B2(+/−)). Adiponectin-Cre mice were generously provided by Dr Evan
Rosen, Beth Israel Deaconess Medical Centre, Harvard Medical School,
Boston, MA, USA. Animal procedures conducted on Ad-B2(+/−) and
Ad-B2(−/−) mice were approved by the University of Aberdeen Ethics
Review Board and performed under project licenses (PPL: P94B395EO and
PFAD33FA2) approved by the UK Home Office. Calculations were
performed to estimate mouse sample size (n) required to ensure adequate
power to detect an effect. For studies performed at thermoneutrality,
11-week-old group-housed male mice were placed at 30°C for 21 weeks and
exposed to a 12-h/12-h light-dark period. Micewere always given ad libitum
access to water and a standard rodent chow diet [CRM (P) 801722, Special
Diets Services] unless otherwise stated. Male Ad-B2(+/−) mice that were
littermates to Ad-B2(−/−) male mice were used as controls. AAV-TBG-iCre
experiments were performed at standard housing temperatures (21°C) using
male and female Ad-B2(−/−) mice, which were group housed by sex and
exposed to a 12-h/12-h light-dark period. Tissues were rapidly dissected
post-mortem, frozen in liquid nitrogen then stored at −70°C.
Metabolic studies
Fat and lean mass levels were measured in Ad-B2(+/−) and Ad-B2(−/−) mice
by DEXA (Lunar PIXImus) after being housed at thermoneutrality for 8
and 21 weeks. For AAV-TBG-iCre experiments, fat and lean mass levels
were measured in 8- to 12-week-old Ad-B2(−/−) male and female mice fed
a chow diet and kept at standard housing temperatures using the
EchoMRI™-500 body composition analyser (Zinsser Analytic GmbH)
and then at 2 and 4 weeks after being fed a high-fat diet [60% kcal from fat
(D12492), Research Diets]. Prior to glucose tolerance tests, mice were
placed in clean cages and food was withheld for 5 h. Basal glucose
readings (0 min) were determined by glucometer readings (AlphaTrak® II,
Zoetisus) from tail punctures. Mice were then given a 2 mg/g d-glucose
(Sigma-Aldrich) bolus by intraperitoneal injection. Blood glucose levels
were monitored at 15, 30, 60 and 120 min. Mice had ad libitum access to
water throughout.
AAV-TBG-iCre vector delivery
Prior to AAV vector injection, 8- to 12-week-old male and femaleAd-B2(−/−)
mice fed a chow diet were randomised into two groups after basal body
weights, glucose tolerance, fat and lean mass levels had been determined.
Ad-B2(−/−) mice were then injected with 1.5×1011 genome copies of AAV-
TBG-iCre (Vector Biolabs, #VB1724) or AAV-TBG-eGFP (#VB1743)
control vector via the intraperitoneal route (Ballantyne et al., 2016; Mehta
et al., 2017). Ad-B2(−/−) micewere then fed a high-fat diet [60% kcal from fat
(D12492), Research Diets] for 4 weeks at standard housing temperatures. All
mice had ad libitum access to food and water unless otherwise stated.
Gene expression
Total RNA was extracted from frozen tissues using an RNeasy mini kit
(Qiagen) following the manufacturer’s protocol. Equal quantities of
RNA were DNase I treated (Sigma-Aldrich) then reverse transcribed with
M-MLV reverse transcriptase, 5× reaction buffer, deoxynucleoside
triphosphates and random primers (Promega). Real-time quantitative PCR
was performed on a CFX384 Touch™ Real-Time PCR Detection System
(Bio-Rad). No template controls and no reverse transcriptase controls were
performed for every gene analysed. The geometric mean of three stable
reference genes (Nono, Ywhaz and Hprt) was used for normalisation.
Serum analysis
Blood was collected from 32-week-old chow-fed mice (thermoneutrality) or
12- to 16-week-old high-fat diet-fed mice (standard housing temperatures)
fasted for 5 h by cardiac puncture. Blood was collected and inverted in
SST™ amber tubes (BD Microtainer®) and incubated at room temperature
for 30 min. Samples were then centrifuged at 12,000 g for 10 min and the
separated serum collected. Insulin, adiponectin, leptin, AST and ALT
analysis was performed at the Core Biochemical Assay Laboratory
(Cambridge, UK). Glucose levels were determined using a Glucose
Colorimetric Assay Kit (Cayman Chemical), following the
manufacturer’s protocol provided. Serum triglyceride levels were
determined using a Triglyceride Liquid Assay (Sentinel Diagnostics),
following the manufacturer’s instructions. QUICKI was calculated from
fasting glucose (mg/dl) and insulin (µU/ml) values as previously described
(Katz et al., 2000). QUICKI=1/[log(I0)+log(G0)], where I0 is fasting insulin
and G0 is fasting glucose. QUICKI is a dimensionless index without units.
Liver triglyceride assay
Frozen liver tissue samples were weighed and then homogenised in 1 ml of
PBS. Samples were kept on ice at all times. Liver lysates were centrifuged at
12,000 g for 10 min at 4°C. The supernatant was collected and triglyceride
levels were determined using a Triglyceride Liquid Assay (Sentinel
Diagnostics), following the manufacturer’s instructions. Triglyceride
levels were then normalised to individual tissue weights.
Generation of BSCL2 KO HepG2 cell lines by CRISPR/Cas9
HepG2 cells (Agouni et al., 2011) were cultured in Dulbecco’s modified
Eagle medium containing low glucose (1 g/l) and supplemented with 10%
fetal bovine serum, 2% glutamine and 1% sodium pyruvate. Cells were
maintained in a humidified incubator at 37°C with 5% CO2, HepG2 cells
have not recently been authenticated or tested for contamination. Two
gRNA sequences were identified using the online CRISPR guide tool
software (http://crispr.mit.edu/) to target exon 2 of BSCL2 and ligated into
pX330 (gRNA #1: 5′-TCTTGGCAGGCCGTGCCCGC-3′) and pX459
(gRNA #2: 5′-GTGGCTGACTGTCGGCATAT-3′) plasmids (#42230 and
#62988, respectively; Addgene). HepG2 cells (1×106) were electroporated
with 5 µg control (Ctrl) or gRNA plasmids using a Cell Line Nucleofector
Kit V (Lonza, VCA-1003) and Nucleofector 2b Device (Lonza) using
program T-28.
Western blot analysis
HepG2 cell monolayers were scraped in RIPA lysis buffer containing
cOmplete protease inhibitor cocktail (Roche). Protein concentrations were
determined by BCA assay (Thermo Fisher Scientific). SDS-PAGE was
performed using equal quantities of protein, which were transferred to
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polyvinylidene fluoride membrane using standard protocols. Primary
antibodies used at 1:1000 dilution included anti-BSCL2 (#23846, Cell
Signaling Technology) and anti-calnexin (ab75801, Abcam). Anti-rabbit
horseradish peroxidase-conjugated secondary antibody was used at 1:5000
dilution (#7074, Cell Signaling Technology) and was visualized using
enhanced chemiluminescence (ECL substrate, Illuminata).
Statistical analyses
All data are presented as the mean±s.e.m. and were analysed by an unpaired
two-tailed Student’s t-test, one-way analysis of variance (ANOVA) with
Tukey post hoc test or two-way repeated measures ANOVAwith Bonferroni
post hoc test as appropriate using GraphPad Prism. P<0.05 was considered
statistically significant.
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